Rami Elghandour Fully Exits Position in Arcellx, Inc. Following Gilead Merger

On April 28, 2026, Rami Elghandour filed Amendment No. 3 to his Schedule 13D, reporting that he no longer holds any shares of Arcellx, Inc. (ACLX). This exit follows the completion of a merger agreement dated February 22, 2026, between Arcellx, Inc., Gilead Sciences, Inc. (Parent), and Ravens Sub, Inc. (Purchaser). Under the terms of the agreement, Purchaser completed a tender offer for all outstanding common stock of the Issuer at a price of $115.00 per share in cash, plus one contractual contingent value right (CVR) worth a potential $5.00 milestone payment. Pursuant to the merger, which closed on April 28, 2026, Arcellx became a wholly owned subsidiary of Gilead Sciences. Mr. Elghandour tendered all his shares in the offer. Additionally, all outstanding stock options and restricted stock units (RSUs) held by him were canceled and converted into the right to receive the cash merger consideration and CVRs. Consequently, the reporting person has ceased to beneficially own any shares of common stock in the Issuer.